NCT02355431 - Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations | Biotech Hunter

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions

Solid Tumors and Hematologic MalignancyNSCLC (Non-small Cell Lung Carcinoma)

Interventions

DRUG

Itacitinib

tablets to be administered by mouth once daily at dose selected from safety run-in phase

DRUG

erlotinib

150 mg tablets administered by mouth once daily at total daily dose of 150 mg

DRUG

placebo

matching placebo tablets to be administered by mouth at dose selected from safety run-in phase

Trial Locations (1)

Ogden